Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Replimune Group Inc (NQ: REPL )

18.99 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 18.99
Bid (Size) 16.58 (1)
Ask (Size) 21.75 (1)
Prev. Close 18.99
Today's Range 18.99 - 18.99
52wk Range 13.84 - 29.52
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recap: Replimune Group Q4 Earnings
 
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga

Performance

YTD
-27.93%
-27.93%
1 Month
+8.51%
+8.51%
3 Month
-14.88%
-14.88%
6 Month
-7.23%
-7.23%
1 Year
+30.70%
+30.70%

More News

Read More
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform
Via Benzinga
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
Via Benzinga
Replimune Group: Q2 Earnings Insights
Via Benzinga
Analyst Ratings for Replimune Group
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Analyst Ratings for Replimune Group
Via Benzinga
Replimune Group: Q3 Earnings Insights
Via Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts
Via Benzinga
Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday
Via Benzinga
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
Via Benzinga
Replimune Group: Q4 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.